Since activated B cells, in addition to activated T cells, can express PD-1, the therapeutic effect of PD-1/CTLA4 blockade against EBV-induced lymphomas in humanized mice could potentially involve “off-target” effects directed against EBV+ lymphoma cells rather than enhancement of the T cell anti-tumor response. The gene discussed is CTLA4; the disease is neoplasm.